Key Takeaways
- Mixed Earnings and Tech Slump: Netflix (NFLX) and Intuitive Surgical (ISRG) reported Q2 results after the bell, with NFLX missing revenue estimates and issuing a cautious Q3 outlook, while ISRG beat on both top and bottom lines.
- Geopolitical Escalation: Reports of U.S. fighter jet strikes on Iran's Iranshahr Airport and surrounding coastal defenses have heightened Middle East tensions, contributing to a late-session market sell-off.
- FDA Milestone for Merck: Merck (MRK) received landmark FDA approval for Lipfendra, the first once-daily oral PCSK9 inhibitor, a major win for its post-Keytruda growth strategy.
- Trade Tensions Rise: The U.S. imposed a 25% tariff on certain Brazilian goods, prompting Brazil to activate its Economic Reciprocity Law and challenge the measures at the WTO.
- Credit Action for Baker Hughes: S&P Global downgraded Baker Hughes (BKR) to 'A-' following the completion of its $13.6 billion acquisition of Chart Industries, citing increased leverage.
Tech Earnings: A Tale of Two Reports
Netflix (NFLX) shares faced pressure in after-hours trading after the streaming giant reported Q2 revenue of $12.56 billion, slightly missing the $12.58 billion consensus. While EPS of $0.80 beat estimates by a penny, the company’s Q3 guidance for revenue ($12.86 billion vs. $13.0 billion est.) and EPS ($0.82 vs. $0.84 est.) suggests a cooling growth trajectory. Management noted that advertising revenue remains on track to reach approximately $3 billion by 2026, though free cash flow for the quarter came in significantly lower than expected at $1.53 billion.
In contrast, Intuitive Surgical (ISRG) delivered a robust beat, reporting Q2 revenue of $2.892 billion against the $2.820 billion expected. The robotic surgery leader posted adjusted EPS of $2.80, far outstripping the $2.50 analyst estimate. Despite an ongoing Class II recall of certain components, the company narrowed its full-year da Vinci procedure growth forecast to 13.5%–15.5%, signaling confidence in the rollout of its next-generation da Vinci 5 platform.
Geopolitical and Trade Volatility
Market sentiment soured late in the day following reports from Tasnim News that U.S. fighter jets launched a missile attack on Iranshahr Airport in southern Iran. Local residents reported three loud explosions, and the strikes are believed to be part of a broader campaign to degrade Iranian military capabilities in the Strait of Hormuz. This escalation follows a series of tit-for-tat strikes in the region, fueling fears of a wider conflict that could impact global energy supplies.
Simultaneously, a new trade front opened as the U.S. Trade Representative (USTR) finalized 25% tariffs on various Brazilian imports. Brazil’s Vice President Geraldo Alckmin condemned the move as "unfair and unreasonable," noting that the U.S. already maintains a significant trade surplus with the country. Brazil has vowed to use its new reciprocity law to impose counter-tariffs, adding another layer of uncertainty to the global trading environment.
Healthcare and Defense Developments
Merck (MRK) secured a pivotal victory with the FDA approval of Lipfendra (enlicitide). As the first oral PCSK9 inhibitor, the drug offers a convenient alternative to existing injectable therapies like Repatha. Analysts expect the drug to achieve multi-billion-dollar annual sales, providing a critical revenue stream as Merck prepares for the eventual patent cliff of its blockbuster cancer drug, Keytruda.
In the defense sector, the U.S. State Department approved an $80.1 million sale of Switchblade 300 Block 20 miniature aerial missile systems to Greece. The deal benefits AeroVironment (AVAV), the manufacturer of the "kamikaze" drones, which have seen increased demand following their performance in recent European conflicts.
Market Summary
The major U.S. indices closed unofficially lower, led by a 1.52% drop in the Nasdaq (^IXIC) as semiconductor stocks continued their week-long slide. The S&P 500 (^GSPC) fell 0.53%, while the Dow Jones Industrial Average (^DJI) proved more resilient, declining only 0.30% thanks to gains in healthcare components like UnitedHealth (UNH). Investors remain cautious as they balance strong corporate earnings against a deteriorating geopolitical backdrop and shifting trade policies.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.